What is the recommended dose of diltiazem (intravenous) for infusion in atrial fibrillation (AF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Intravenous Diltiazem for Atrial Fibrillation

For atrial fibrillation with rapid ventricular response, the recommended diltiazem infusion dosing is an initial bolus of 0.25 mg/kg (approximately 15-20 mg) administered over 2 minutes, followed by a continuous infusion starting at 5-15 mg/hour, titrated to heart rate response. 1, 2

Initial Bolus Dosing

  • Initial bolus dose: 0.25 mg/kg actual body weight administered over 2 minutes (approximately 15-20 mg for average adult) 1, 2
  • If response is inadequate after 15 minutes, a second bolus of 0.35 mg/kg (approximately 20-25 mg) may be administered over 2 minutes 1
  • Some patients may respond to a lower initial dose of 0.15 mg/kg, though duration of action may be shorter 1
  • Low-dose diltiazem (≤0.2 mg/kg) has shown similar efficacy with lower rates of hypotension compared to standard dosing 3

Continuous Infusion

  • Begin continuous infusion immediately following bolus administration 1
  • Recommended initial infusion rate: 10 mg/hour 1, 2
  • Some patients may maintain response at 5 mg/hour 1
  • Infusion rate may be increased in 5 mg/hour increments up to 15 mg/hour as needed 1, 2
  • Maintenance infusion range: 5-15 mg/hour, titrated to heart rate response 2, 1
  • Maximum recommended infusion duration: 24 hours 1

Dilution Guidelines

  • Diltiazem should be diluted in either Normal Saline, D5W, or D5W/0.45% NaCl 1
  • Diluted solution should be refrigerated until use and used within 24 hours 1
  • Common dilution: 125 mg in 100 mL (1 mg/mL) or 250 mg in 250 mL (0.83 mg/mL) 1

Monitoring and Precautions

  • Monitor heart rate and blood pressure continuously during administration 2
  • Target heart rate is generally considered controlled when between 60-80 bpm at rest 2
  • Avoid in patients with heart failure with reduced ejection fraction (LVEF ≤40%) due to negative inotropic effects 2
  • Use with caution in combination with beta-blockers 2
  • Reduce dose in patients with hepatic impairment 2
  • Start with smaller dose in patients with renal impairment 2

Transition to Oral Therapy

  • For continued rate control, transition to oral diltiazem can be initiated while IV infusion continues 4
  • Oral dosing: 60 mg three times daily up to 360 mg total daily dose, or 120-360 mg once daily with modified-release formulation 2
  • Continue IV infusion for approximately 4 hours after first oral dose to ensure adequate transition 4
  • Success rate of maintaining heart rate control during transition from IV to oral therapy is approximately 77% 4

Alternative Rate Control Agents

  • Beta-blockers (metoprolol, esmolol) are also first-line agents for rate control in AF 2
  • Digoxin may be used in patients with heart failure with reduced ejection fraction 2
  • In patients with severely impaired LV function, consider amiodarone for rate control 2

Remember that diltiazem should only be used in patients with preserved left ventricular function (LVEF >40%), as it can worsen heart failure in patients with reduced ejection fraction 2.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.